Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2022
- Source ID
- 10.1016/s1473-3099(21)00764-7
Entities
People
- Agustin Bueso
- Aiying Chen
- Anne-laure Chabanon
- Ansoyta Said
- Arnel Joaquin
- Bo Fu
- Brandon J Essink
- Carlos A. Diazgranados
- Catherine Moreau
- Dalia Von Barbier
- David Diemert
- Denise Lopez
- Doris M Rivera M
- Enrique Rivas
- Fernanda Tavares-da-silva
- Guy De Bruyn
- Helene Janosczyk
- Jiayuan Shi
- John Treanor
- Judith M White
- Lawrence D. Sher
- Lode Schuerman
- Marguerite Koutsoukos
- Maria Angeles Ceregido
- Marie-helene Grillet
- Maryam Keshtkar-Jahromi
- Matthew I Bonaparte
- Michael C. Keefer
- Nadine G Rouphael
- Natalya Romanyak
- Nelson Michael
- Nicole A Grunenberg
- Onyema Ogbuagu
- Randall Severance
- Richard Canter
- Roger Masotti
- Roman M Chicz
- Sandra Mendoza
- Saranya Sridhar
- Shelly Ramirez
- Sonal S Munsiff
- Stephen R Walsh
- Stephen Savarino
- Tina Tong
- Vanessa N Raabe
- Ya Meng
Organizations
- Sanofi Pasteur